Roche adds $25M to Halozyme pact for fresh tar­gets; FDA OKs car­dio in­di­ca­tion for J&J's In­vokana

→ Build­ing on a 12-year-old part­ner­ship, Roche has doled out $25 mil­lion to de­vel­op up to three more tar­gets on Halozyme’s En­hanze drug de­liv­ery tech — a plat­form that played a role in the de­vel­op­ment of block­busters Rit­ux­an and Her­ceptin. The San Diego biotech $HA­LO stands to earn some­where be­tween $160 mil­lion and $165 mil­lion per tar­get for each pro­gram pur­sued. Roche al­ready has a clin­i­cal stage tar­get in mind for one of them, while keep­ing the oth­er two as op­tions to be ma­te­ri­al­ized with­in four years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER